European authorities have revoked a Regeneron patent covering a genetic modification technique used to generate mouse monoclonal antibody (mAb) production platforms after an appeal by several European firms.
A government funded bioprocessing institute is helping to drive biopharma investment and retrain workers in Ireland, and Biopharma-Reporter.com visited to find out what happens in this "flight simulator for biopharma manufacturing."
Recent investments in antibody-drug conjugate (ADC) technology will translate into more products on the market, but it will take time says Polytherics who has extended its licensing deal with MacroGenics.
Crescendo Biologics has secured funding to develop a range of Ab fragment-based drugs using its genetically modified mouse platform, including a psoriasis treament that could rival blockbusters like Remicade and Humira.
Big Pharma interest in antibody drug conjugates (ADC) hit another high this week with Roche ,Novartis and AstraZeneca each announcing investments that boost their ability to develop and manufacture these small-molecule monoclonal antibody (mAb) drug...